218 related articles for article (PubMed ID: 15146248)
41. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.
Weng J; Rawal S; Chu F; Park HJ; Sharma R; Delgado DA; Fayad L; Fanale M; Romaguera J; Luong A; Kwak LW; Neelapu SS
Blood; 2012 Aug; 120(8):1613-23. PubMed ID: 22645177
[TBL] [Abstract][Full Text] [Related]
42. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
Ebert LM; Liu YC; Clements CS; Robson NC; Jackson HM; Markby JL; Dimopoulos N; Tan BS; Luescher IF; Davis ID; Rossjohn J; Cebon J; Purcell AW; Chen W
Cancer Res; 2009 Feb; 69(3):1046-54. PubMed ID: 19176376
[TBL] [Abstract][Full Text] [Related]
43. Follicular lymphoma: a model of lymphoid tumor progression in man.
Zelenetz AD; Campbell MJ; Bahler DW; Takahashi S; Oren R; Esserman L; Umetsu DT; Kwak LW; Maloney DG; Brown S
Ann Oncol; 1991 Feb; 2 Suppl 2():115-22. PubMed ID: 2049308
[TBL] [Abstract][Full Text] [Related]
44. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma.
Bendandi M
Expert Rev Anticancer Ther; 2001 Jun; 1(1):65-72. PubMed ID: 12113135
[TBL] [Abstract][Full Text] [Related]
45. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
46. The role of idiotype vaccines in the treatment of human B-cell malignancies.
Bendandi M
Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
[TBL] [Abstract][Full Text] [Related]
47. Evidence for idiotype-directed immunosurveillance is restricted to follicular lymphoma and attributable to somatic hypermutation.
Papaioannou D; Strothmeyer AM; Dühren-von Minden M; Keppler-Hafkemeyer A; Zirlik K; Mikesch K; van Bergen CA; Navarrete MA; Veelken H
Haematologica; 2015 Apr; 100(4):e143-6. PubMed ID: 25616573
[No Abstract] [Full Text] [Related]
48. An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
Mateo L; Gardner J; Chen Q; Schmidt C; Down M; Elliott SL; Pye SJ; Firat H; Lemonnier FA; Cebon J; Suhrbier A
J Immunol; 1999 Oct; 163(7):4058-63. PubMed ID: 10491010
[TBL] [Abstract][Full Text] [Related]
49. Escherichia coli-based production of a tumor idiotype antibody fragment--tetanus toxin fragment C fusion protein vaccine for B cell lymphoma.
Patel KG; Ng PP; Levy S; Levy R; Swartz JR
Protein Expr Purif; 2011 Jan; 75(1):15-20. PubMed ID: 20851769
[TBL] [Abstract][Full Text] [Related]
50. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
[TBL] [Abstract][Full Text] [Related]
51. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
[TBL] [Abstract][Full Text] [Related]
52. A novel multi-epitope peptide vaccine against cancer: an in silico approach.
Nezafat N; Ghasemi Y; Javadi G; Khoshnoud MJ; Omidinia E
J Theor Biol; 2014 May; 349():121-34. PubMed ID: 24512916
[TBL] [Abstract][Full Text] [Related]
53. Generation of heavy chain-loss mutants in a B cell hybrid mediated by syngeneic idiotype-specific spleen cells.
Ghosh SK; Bankert RB
J Immunol; 1984 Sep; 133(3):1677-82. PubMed ID: 6205092
[TBL] [Abstract][Full Text] [Related]
54. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
[TBL] [Abstract][Full Text] [Related]
55. Vaccination strategies in the treatment of lymphomas.
Veelken H; Osterroth F
Oncology; 2002; 62(3):187-200. PubMed ID: 12065865
[TBL] [Abstract][Full Text] [Related]
56. Human tumor antigens for cancer vaccine development.
Wang RF; Rosenberg SA
Immunol Rev; 1999 Aug; 170():85-100. PubMed ID: 10566144
[TBL] [Abstract][Full Text] [Related]
57. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity.
Qin H; Cha SC; Neelapu SS; Lou Y; Wei J; Liu YJ; Kwak LW
Blood; 2009 Nov; 114(19):4142-9. PubMed ID: 19749091
[TBL] [Abstract][Full Text] [Related]
58. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.
Kafi K; Betting DJ; Yamada RE; Bacica M; Steward KK; Timmerman JM
Mol Immunol; 2009 Jan; 46(3):448-56. PubMed ID: 19046770
[TBL] [Abstract][Full Text] [Related]
59. Remodeling of the epitope repertoire of a candidate idiotype vaccine by targeting to lysosomal degradation in dendritic cells.
Martorelli D; Coppotelli G; Muraro E; Dolcetti R; Masucci MG
Cancer Immunol Immunother; 2012 Jun; 61(6):881-92. PubMed ID: 22089857
[TBL] [Abstract][Full Text] [Related]
60. Anti-idiotype vaccines for human follicular lymphoma.
Bendandi M
Leukemia; 2000 Aug; 14(8):1333-9. PubMed ID: 10942225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
